Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 2/20 | 0.32 |
| ▸ | PPARD | Q03181 | 2/20 | 0.31 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | PTGFR | P43088 | 6/20 | 0.31 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.31 |
| ▸ | MLYCD | O95822 | 1/20 | 0.30 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.30 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.30 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.30 |
| ▸ | KLK6 | Q92876 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.30 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.30 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL211855 | 0.94 | MAPK14 (0.31) | MAPK14NPC1NTRK1 | |
| SCHEMBL213118 | 0.87 | FOLH1 (0.34) | MAPK14NPC1PTGFRNTRK1MLYCD | |
| SCHEMBL210986 | 0.86 | SCD5 (0.35) | THRB | |
| SCHEMBL210624 | 0.85 | MAPT (0.41) | NPC1THRB | |
| SCHEMBL212860 | 0.82 | KDM4E (0.38) | NPC1 | |
| SCHEMBL211757 | 0.81 | CSNK2A2 (0.41) | PPARGNPC1 | |
| SCHEMBL2726246 | 0.81 | NTRK1 (0.33) | MAPK14NPC1NTRK1PRSS1PRSS2 | |
| SCHEMBL212595 | 0.81 | MAPT (0.34) | THRB | |
| SCHEMBL211532 | 0.81 | SMN1; SMN2 (0.35) | MAPK14NPC1 | |
| SCHEMBL211943 | 0.81 | MAPT (0.41) | NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8895582-B2 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. (US) | 2014-11-25 | — | — | US | disclosed |
| US-8759374-B2 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. (US) | 2014-06-24 | — | — | US | disclosed |
| US-20130053348-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | QIAN XIANGPING (US) | 2013-02-28 | — | — | US | disclosed |
| US-20120135964-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | QIAN XIANGPING (US) | 2012-05-31 | — | — | US | disclosed |
| US-8088793-B2 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20090275537-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275537-A1 | Certain chemical entities, compositions, and methods | MYLK, MYH2, MYH10 | MAPK14 3484/4885PPARD 1645/4885PPARG 860/4885 |
| US-20120135964-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | MYLK, MYH2, MYH10 | MAPK14 3484/4885PPARD 1645/4885PPARG 860/4885 |
| US-20130053348-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | MYLK, MYH2, MYH10 | MAPK14 3484/4885PPARD 1645/4885PPARG 860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.